Form 4: UroGen Pharma Executive Mark Schoenberg Reports Stock Transactions
SEC Form 4 Filing
Chief Medical Officer Mark Schoenberg reports acquisition and disposal of UroGen Pharma shares and restricted stock units on January 31, 2025.
Summary
- Mark Schoenberg, Chief Medical Officer of UroGen Pharma Ltd., filed a Form 4 detailing changes in beneficial ownership.
- On January 31, 2025, Schoenberg acquired shares through the vesting of restricted stock units (RSUs) and disposed of shares to cover withholding tax obligations.
- Specifically, 1,334 shares vested from a 2022 grant, 3,333 shares vested from a 2023 grant, and 3,333 shares vested from a 2024 grant.
- He also acquired 20,000 RSUs that will vest in three equal annual installments starting January 31, 2026.
- Schoenberg sold 759 shares at $11.14 and 1,896 shares at $11.14 to cover tax obligations.
- Following these transactions, Schoenberg directly owns 148,540 ordinary shares and 29,999 restricted stock units.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The transactions are routine and expected as part of executive compensation. There's no indication of unusual activity or concern.
Positives
- The acquisition of shares through RSU vesting indicates confidence in the company's future performance.
Negatives
- The sale of shares to cover tax obligations, while common, slightly reduces Schoenberg's holdings.
Future Outlook
The vesting schedule of the newly granted RSUs indicates a continued alignment of the executive's interests with the long-term performance of the company.
Industry Context
Insider transactions are routinely monitored by investors to gauge executive sentiment and confidence in the company's prospects. RSU grants are a common form of executive compensation in the pharmaceutical industry.
Comparison to Industry Standards
- Stock ownership and RSU grants are standard compensation practices in the pharmaceutical industry, aligning executive incentives with shareholder value.
- Comparing Schoenberg's holdings and transactions to those of executives at similar-sized biotech companies like BioCryst Pharmaceuticals or Radius Health could provide a benchmark for assessing the magnitude of his stake.
Stakeholder Impact
- The transactions are unlikely to have a significant impact on stakeholders, as they are related to routine executive compensation.
Key Dates
| Date | Description |
|---|---|
| January 31, 2022 | Reporting person was granted RSUs representing 4,000 ordinary shares. |
| January 31, 2023 | Reporting person was granted RSUs representing 10,000 ordinary shares. |
| January 31, 2024 | Reporting person was granted RSUs representing 10,000 ordinary shares. |
| January 31, 2025 | Date of transactions: vesting of RSUs and sale of shares for tax obligations. |
| January 31, 2026 | First vesting date for the 20,000 RSUs granted on January 31, 2025. |
| January 31, 2027 | Second vesting date for the 20,000 RSUs granted on January 31, 2025. |
| January 31, 2028 | Third vesting date for the 20,000 RSUs granted on January 31, 2025. |
| February 04, 2025 | Date of Form 4 filing. |
Keywords
UroGen Pharma, URGN, Mark Schoenberg, Form 4, Beneficial Ownership, Restricted Stock Units, RSU, Insider Trading, Chief Medical Officer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.